37 completed, 2 recruiting, 2 terminated, 2 withdrawn. 17 Phase 3, 11 Phase 2, 8 Phase 4, 7 Phase 1, 1 Not applicable.
Follow GSK573719: new trials by email Literature Review of GSK573719 trials Research Report on GSK573719
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VENTURI (VENTilation Using Respiratory Imaging) Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder - Asthma | Phase 2 | Recruiting | University of Alabama at Birmingham | 20 | 2026-03-15 | 2026-04-13 |
| Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD Tiotropium, Olodaterol, Umeclidinium - COPD (Chronic Obstructive Pulmonary Disease) | Not applicable | Suspended | Medical University of Bialystok | 100 | 2024-03-11 | 2026-10-02 |
| ANTES B+ Clinical Trial Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir - Chronic Obstructive Pulmonary Disease | Phase 4 | Terminated | Fundacio Privada Mon Clinic Barcelona | 48 | 2024-02-29 | 2025-08-14 |
| Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ) - COPD (Chronic Obstructive Pulmonary Disease) | Phase 4 | Recruiting | University of Tennessee Graduate School of Medicine | 72 | 2023-12-05 | 2026-10-19 |
| Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure Vilanterol / Umeclidinium (25/62.5 mcg), Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg), Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg - COPD Bronchitis, Pollution Related Respiratory Disorder | Phase 4 | Unknown | National Institute of Respiratory Diseases, Mexico | 128 | 2023-11-15 | 2024-08-26 |
| A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD) Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg) - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 9117 | 2021-12-17 | 2023-10-19 | |
| Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure Umeclidinium/vilanterol, Placebo - Copd, Heart Failure | Phase 4 | Completed | Luis Puente Maestu | 60 | 2021-05-21 | 2026-09-21 |
| A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD) Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 11296 | 2019-06-10 | 2021-11-15 | |
| Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients Umeclidinium / Vilanterol Dry Powder Inhaler, Placebo - COPD | Phase 4 | Completed | Gary L. Pierce | 15 | 2019-01-24 | 2020-07-14 |
| Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease Bronchodilator Agents - Pulmonary Disease, Chronic Obstructive | Phase 4 | Terminated | Università degli Studi di Ferrara | 843 | 2018-11-11 | 2022-12-28 |
| Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics Anoro Ellipta, Arnuity Ellipta - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | University of Virginia | 95 | 2017-11-05 | 2024-11-18 |
| Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes. Fluticasone Furoate/Vilanterol 100/25 mcgs, Umeclidinium/Vilanterol 62.5/25 mcgs - COPD | Phase 4 | Completed | National Institute of Respiratory Diseases, Mexico | 133 | 2017-09-19 | 2022-04-22 |
| Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease Glycopyrronium/Formoterol Fumarate, umeclidinium/vilanterol - Chronic Obstructive Pulmonary Disease COPD | Phase 3 | Completed | AstraZeneca | 1119 | 2017-05-25 | 2019-05-22 |
| A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg, Fluticasone furoate 100 mcg + Vilanterol 25 mcg, Umeclidinium 62.5 mcg - Pulmonary Disease, Chronic Obstructive | Phase 3 | Withdrawn | GlaxoSmithKline | 2016-06-01 | 2016-07-22 | |
| A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects Umeclidinium, Vehicle - Hyperhidrosis | Phase 2 | Completed | Stiefel, a GSK Company | 58 | 2016-03-07 | 2018-02-09 |
| Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis Umeclidinium, Vehicle - Hyperhidrosis | Phase 2 | Completed | GlaxoSmithKline | 28 | 2015-11-23 | 2018-10-11 |
| Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD) Batefenterol, Umeclidinium/ Vilanterol, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | GlaxoSmithKline | 325 | 2015-11-06 | 2019-07-16 |
| Efficacy and Safety Study of QVA149 in COPD Patients QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol) - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 357 | 2015-07-28 | 2017-12-26 |
| Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients. QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol ) - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 355 | 2015-07-27 | 2018-04-02 |
| A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Umeclidinium, Glycopyrronium - Pulmonary Disease, Chronic Obstructive | Phase 4 | Completed | GlaxoSmithKline | 1036 | 2014-09-26 | 2018-05-02 |
Showing 20 of 46. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (41) · Asthma (3) · Bronchitis, Chronic (3) · Emphysema (3) · Hyperhidrosis (2) · Dyspnea (1) · Heart Failure (1) · Motor Activity (1)
GlaxoSmithKline (29) · Boehringer Ingelheim (2) · National Institute of Respiratory Diseases, Mexico (2) · Novartis Pharmaceuticals (2) · AstraZeneca (1) · Fundacio Privada Mon Clinic Barcelona (1) · Gary L. Pierce (1) · Luis Puente Maestu (1) · Medical University of Bialystok (1) · Queen's University (1) · Stiefel, a GSK Company (1) · University of Alabama at Birmingham (1) · University of Tennessee Graduate School of Medicine (1) · University of Virginia (1) · Università degli Studi di Ferrara (1)
United States (25) · Germany (16) · Canada (9) · Russia (7) · Ukraine (7) · Argentina (6) · Romania (6) · United Kingdom (6) · Japan (5) · Mexico (5) · South Africa (5) · Bulgaria (4) · Chile (4) · Estonia (4) · France (4)
Denis E O'Donnell, MD, FRCPC (1) · Gary L Pierce, PhD (1) · Kun Qing, PhD (1) · Luis Puente-Maestu, Prof (1) · Robert M Mroz, professor (1) · Yun M Shim, MD (1)
PMID 27796912, PMID 24835833, PMID 28993871, PMID 29773969, PMID 20956145, PMID 23155808, PMID 23681559, PMID 23949963, PMID 24385182, PMID 24393134, PMID 25146558, PMID 25464907, PMID 26006754, PMID 26782971, PMID 27103795, PMID 27730198, PMID 31267366, PMID 32349720, PMID 39968202
2015 (1), 2019 (1), 2023 (1)